{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:04Z","timestamp":1761871084927,"version":"build-2065373602"},"reference-count":93,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.clml.2018.03.014","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T11:14:20Z","timestamp":1522754060000},"page":"301-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["\u201cSociety of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions\u201d\u2014Treatment of ALL"],"prefix":"10.1016","volume":"18","author":[{"given":"Sabina","family":"Chiaretti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Hoelzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.03.014_bib1","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.014_bib2","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.014_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3324\/haematol.10385","article-title":"Absence of prognostic impact of CD13 and\/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial","volume":"92","author":"Vitale","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.03.014_bib4","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","article-title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.03.014_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/sj.leu.2404952","article-title":"Validation of NG2 antigen in identifying BP-ALL patients with MLL rearrangements using qualitative and quantitative flow cytometry: a prospective study","volume":"22","author":"Zangrando","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.014_bib6","first-page":"632","article-title":"BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia","volume":"7","author":"Tang","year":"2015","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.clml.2018.03.014_bib7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3324\/haematol.2009.011346","article-title":"Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia","volume":"95","author":"Burmeister","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.03.014_bib10","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1200\/JCO.2013.48.9377","article-title":"Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97\/99 and UKALL2003 trials","volume":"31","author":"Moorman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2013.51.3242","article-title":"IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome","volume":"32","author":"Russell","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2018.03.014_bib13","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/asheducation-2015.1.406","article-title":"Management of adult Ph-positive acute lymphoblastic leukemia","volume":"2015","author":"Chiaretti","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2018.03.014_bib14","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood.V96.7.2543","article-title":"New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases","volume":"96","author":"Schneider","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib15","first-page":"613","article-title":"Pediatric leukemia\/lymphoma with t(8;14)(q24;q11)","volume":"6","author":"Lange","year":"1992","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.014_bib16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.clml.2018.03.014_bib17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.03.014_bib18","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1200\/JCO.2008.21.6408","article-title":"IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report","volume":"27","author":"Martinelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib19","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1002\/cncr.29579","article-title":"Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols","volume":"121","author":"Ribera","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.03.014_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.14721","article-title":"Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts","volume":"178","author":"Messina","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.014_bib21","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1172\/JCI61203","article-title":"Molecular genetics of B-precursor acute lymphoblastic leukemia","volume":"122","author":"Mullighan","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2018.03.014_bib22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.03.014_bib23","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/ng.3691","article-title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2018.03.014_bib24","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1200\/EDBK_156628","article-title":"Advances in the genetics and therapy of acute lymphoblastic leukemia","volume":"35","author":"Chiaretti","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2018.03.014_bib25","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib26","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib27","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.014_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.14082","article-title":"Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin\/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia","volume":"174","author":"Della Starza","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.014_bib29","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.clml.2017.08.009","article-title":"Clinical applications and pitfalls of MRD in ALL","volume":"17","author":"Hoelzer","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.03.014_bib30","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib31","first-page":"130","article-title":"Evaluation of minimal residual disease (MRD) and MRD-based treatment decisions in Ph\/BCR-ABL negative adult acute lymphoblastic leukemia (ALL): experience from the German Multicenter Study Group for Adult ALL (GMALL) (abstract 2017)","author":"G\u00f6kbuget","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib32","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.03.014_bib33","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib34","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib35","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.23149","article-title":"Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis","volume":"87","author":"Ram","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.03.014_bib37","doi-asserted-by":"crossref","first-page":"e2014052","DOI":"10.4084\/mjhid.2014.052","article-title":"Treatment of adolescent and young adults with acute lymphoblastic leukemia","volume":"6","author":"Ribera","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2018.03.014_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1159\/000360204","article-title":"Acute lymphoblastic leukemia in adolescents and young adults","volume":"132","author":"Burke","year":"2014","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2018.03.014_bib39","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/CCO.0b013e32835538f8","article-title":"Acute lymphoblastic leukemia in young adults: which treatment?","volume":"24","author":"McNeer","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib40","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/cncr.28930","article-title":"Augmented Berlin-Frankfurt-M\u00fcnster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)","volume":"120","author":"Rytting","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.03.014_bib41","first-page":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL- 2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.014_bib44","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3109\/10428194.2014.991921","article-title":"Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database","volume":"56","author":"Guru Murthy","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.03.014_bib45","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2012-07-379016","article-title":"How I treat older patients with ALL","volume":"122","author":"G\u00f6kbuget","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib46","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib49","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Fo\u00e0","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib50","first-page":"124","article-title":"Nilotinib (Tasigna) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome\/BCR-ABL1 positive acute lymphoblastic leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02) (abstract 798)","author":"Ottmann","year":"2014","journal-title":"Blood"},{"issue":"15 suppl","key":"10.1016\/j.clml.2018.03.014_bib51","article-title":"Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results of a phase II study (abstract 7013)","volume":"35","author":"Short","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib52","first-page":"130","article-title":"First report of the Gimema LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (abstract 99)","author":"Martinelli","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib53","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2013.08.027","volume":"50","author":"Giebel","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2018.03.014_bib55","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.014_bib56","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1182\/blood-2017-03-771121","article-title":"Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia","volume":"130","author":"Carpenter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2018.03.014_bib58","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR\/ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2018.03.014_bib59","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.clml.2018.03.014_bib60","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clml.2018.03.014_bib61","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular\u00a0response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib62","first-page":"1","article-title":"Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed\/refractory acute lymphoblastic leukemia","volume":"18","author":"Hanif","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.03.014_bib63","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.03.014_bib64","first-page":"130","article-title":"Inotuzumab ozogamicin in combination with bosutinib for patients with relapsed or refractory Ph+ ALL or CML in lymphoid blast phase (abstract 143)","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib66","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib67","article-title":"Ruxolitinib or dasatinib in combination with chemotherapy for patients with relapsed\/refractory Philadelphia (Ph)-like acute lymphoblastic leukemia: a phase I-II trial (abstract 1322)","volume":"130","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib68","unstructured":"Chiaretti S, Messina M, Grammatico S, et\u00a0al. Rapid identification of BCR\/ABL1-like acute lymphoblastic leukemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. Br J Haematol, in press."},{"key":"10.1016\/j.clml.2018.03.014_bib69","doi-asserted-by":"crossref","first-page":"e53190","DOI":"10.1371\/journal.pone.0053190","article-title":"FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors","volume":"8","author":"Neumann","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2018.03.014_bib70","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3324\/haematol.2015.141218","article-title":"An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study","volume":"101","author":"Bond","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.03.014_bib71","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a Group for Research on Adult Acute Lymphoblastic Leukemia Study","volume":"35","author":"Bond","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib72","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/leu.2017.10","article-title":"Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia","volume":"31","author":"Peirs","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.014_bib73","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib74","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib76","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.03.014_bib77","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clml.2018.03.014_bib78","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib79","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib80","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.03.014_bib81","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1517\/13543784.2012.679359","article-title":"Inotuzumab ozogamic in in the treatment of B-cell acute lymphoblastic leukemia","volume":"21","author":"Thomas","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2018.03.014_bib82","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","article-title":"Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study","volume":"13","author":"Kantarjian","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib83","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.03.014_bib84","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","article-title":"Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study","volume":"1","author":"DeAngelo","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2018.03.014_bib85","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.03.014_bib86","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed\/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2018.03.014_bib87","article-title":"Interim data from a phase 1 study evaluating pyrrolobenzodiazepine-based antibody drug conjugate ADCT-402 (loncastuximab tesirine) targeting CD19 for relapsed or refractory B-cell acute lymphoblastic leukemia (abstract 1321)","volume":"130","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib88","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.clml.2018.03.014_bib89","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2018.03.014_bib90","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.221.221","article-title":"Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL) (abstract 221)","volume":"128","author":"Grupp","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib91","first-page":"130","article-title":"Phase 1 results of ZUMA-3: KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients with relapsed\/refractory acute lymphoblastic leukemia (R\/R ALL) (abstract 888)","author":"Shah","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.014_bib92","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2018.03.014_bib93","first-page":"130","article-title":"Preliminary results of UCART19, an allogeneic anti-CD19 CAR T-cell product, in a first-in-human trial (CALM) in adult patients with CD19+ relapsed\/refractory B-cell acute lymphoblastic leukemia (abstract 887)","author":"Graham","year":"2017","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501830315X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501830315X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:16Z","timestamp":1761870616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501830315X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S215226501830315X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cSociety of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions\u201d\u2014Treatment of ALL","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}